$186 Million is the total value of SABBY MANAGEMENT, LLC's 93 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPDR GOLD TRcall | $21,446,000 | – | 2,428 | +100.0% | 11.56% | – | |
| New | SPDR S&P 500 ETFcall | $14,987,000 | – | 505 | +100.0% | 8.08% | – | |
| TEUM | New | PARETEUM CORP | $2,901,000 | – | 2,248,578 | +100.0% | 1.56% | – |
| New | BIOHAVEN PHARMACEUTICAL HLDG CO LTDput | $1,719,000 | – | 412 | +100.0% | 0.93% | – | |
| CRMD | New | CORMEDIX INC | $1,590,000 | – | 249,198 | +100.0% | 0.86% | – |
| New | OBALON THERAPEUTICS INC | $1,330,000 | – | 685,661 | +100.0% | 0.72% | – | |
| ARCT | New | ARCTURUS THERAPEUTICS HLDG INC | $1,282,000 | – | 124,843 | +100.0% | 0.69% | – |
| BNTC | New | BENITEC BIOPHARMA LTDadr | $971,000 | – | 1,365,615 | +100.0% | 0.52% | – |
| BHVN | New | BIOHAVEN PHARMACEUTICAL HLDG CO LTD | $828,000 | – | 19,850 | +100.0% | 0.45% | – |
| ONTX | New | ONCONOVA THERAPEUTICS INC | $682,000 | – | 802,846 | +100.0% | 0.37% | – |
| CTXR | New | CITIUS PHARMACEUTICALS INC | $640,000 | – | 845,432 | +100.0% | 0.34% | – |
| New | TOP SHIPS INC | $572,000 | – | 204,227 | +100.0% | 0.31% | – | |
| DMPI | New | DELMAR PHARMACEUTICALS INC | $526,000 | – | 951,454 | +100.0% | 0.28% | – |
| XBIO | New | XENETIC BIOSCIENCES INC | $484,000 | – | 404,550 | +100.0% | 0.26% | – |
| SEEL | New | SEELOS THERAPEUTICS INC | $451,000 | – | 491,237 | +100.0% | 0.24% | – |
| New | GENOCEA BIOSCIENCES INCcall | $429,000 | – | 1,481 | +100.0% | 0.23% | – | |
| VBIV | New | VBI VACCINES INC | $413,000 | – | 876,157 | +100.0% | 0.22% | – |
| PSTV | New | PLUS THERAPEUTICS INC | $389,000 | – | 113,600 | +100.0% | 0.21% | – |
| CUR | New | NEURALSTEM INC | $342,000 | – | 204,823 | +100.0% | 0.18% | – |
| New | KADMON HLDGS INCput | $321,000 | – | 114 | +100.0% | 0.17% | – | |
| HEPA | New | HEPION PHARMACEUTICALS INC | $278,000 | – | 115,000 | +100.0% | 0.15% | – |
| XBIOW | New | XENETIC BIOSCIENCES INC*w | $258,000 | – | 266,789 | +100.0% | 0.14% | – |
| AIM | New | AIM IMMUNOTECH INC | $141,000 | – | 185,171 | +100.0% | 0.08% | – |
| PSTI | New | PLURISTEM THERAPEUTICS INC | $139,000 | – | 37,191 | +100.0% | 0.08% | – |
| ADMP | New | ADAMIS PHARMACEUTICALS CORP | $129,000 | – | 183,359 | +100.0% | 0.07% | – |
| New | PLURISTEM THERAPEUTICS INCput | $67,000 | – | 179 | +100.0% | 0.04% | – | |
| VISL | New | VISLINK TECHNOLOGIES INC | $61,000 | – | 115,314 | +100.0% | 0.03% | – |
| SNES | New | SENESTECH INC COM | $49,000 | – | 48,294 | +100.0% | 0.03% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $44,000 | – | 42,007 | +100.0% | 0.02% | – |
| New | ORAMED PHARMACEUTICALS INCput | $43,000 | – | 135 | +100.0% | 0.02% | – | |
| New | CELSION CORPput | $28,000 | – | 184 | +100.0% | 0.02% | – | |
| TTNP | New | TITAN PHARMACEUTICALS INC | $22,000 | – | 83,218 | +100.0% | 0.01% | – |
| New | ADAMIS PHARMACEUTICALS CORPput | $8,000 | – | 114 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR S&P 500 ETF TRUST UNIT | 37 | Q3 2023 | 49.1% |
| ISHARES TR | 35 | Q3 2023 | 52.2% |
| SPDR S&P BIOTECHNOLOGY | 32 | Q3 2022 | 12.8% |
| AMARIN CORP PLC | 30 | Q4 2021 | 2.0% |
| BIOGEN INC | 24 | Q1 2021 | 26.2% |
| SAREPTA THERAPEUTICS INC | 24 | Q3 2020 | 4.6% |
| BIOGEN INC | 23 | Q1 2021 | 13.7% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2020 | 6.2% |
| BRAINSTORM CELL THERAPEUTICS INC | 21 | Q3 2023 | 1.6% |
| VERTEX PHARMACEUTICALS INC | 20 | Q1 2018 | 12.6% |
View SABBY MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AGM GROUP HOLDINGS, INC. | January 10, 2023 | 627,936 | 2.6% |
| Bit Digital, Inc | January 10, 2023 | 3,166,917 | 3.8% |
| Cingulate Inc. | January 10, 2023 | 10 | 5.0% |
| Context Therapeutics Inc. | January 10, 2023 | 796,706 | 5.0% |
| HeartBeam, Inc. | January 10, 2023 | 271,788 | 3.4% |
| PharmaCyte Biotech, Inc. | January 10, 2023 | 934,456 | 5.0% |
| Rebus Holdings, Inc.Sold out | January 10, 2023 | 0 | 0.0% |
| TANTECH HOLDINGS LTD | January 10, 2023 | 41,500 | 0.6% |
| Quanergy Systems, Inc. | January 04, 2023 | 936,905 | 5.8% |
| TuanChe Ltd | January 04, 2023 | 2,384,713 | 10.0% |
View SABBY MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
View SABBY MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.